Washington, President Donald Trump signed an executive order Thursday directing federal agencies to expedite reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act. Officials said the change recognizes medical use and will ease research barriers, banking access, and tax treatment such as 280E relief. State researchers and attorneys general offered mixed reactions, noting potential benefits for clinical studies and continued regulatory constraints, heightened federal oversight. Cannabis companies and payment firms welcomed the move, citing improved operations and investment prospects. The executive order does not legalize recreational use. Based on 6 articles reviewed and supporting research.
Prepared by Lauren Mitchell and reviewed by editorial team.
Licensed cannabis companies, payment processors, investors, medical researchers, patients seeking clinical trials, and banks are likely to see reduced regulatory barriers, improved access to financial services, and potential tax relief following the rescheduling directive.
Some state officials, law enforcement stakeholders, and opponents of cannabis liberalization may face increased pressure and legal challenges as federal guidance shifts, prompting debates over public health, enforcement, and youth access.
No left-leaning sources found for this story.
Trump Orders Federal Rescheduling To Expand Cannabis Research
Green Stock News Financial Post Benzinga KOAA heidoh.com WISH-TV | Indianapolis News | Indiana Weather | Indiana TrafficNo right-leaning sources found for this story.
Comments